Results 191 to 200 of about 3,775,993 (302)

Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. [PDF]

Curr Issues Mol Biol
Perković D, Petrić M, Maleš M, Erceg Maleš I, Radić M.   +4 more
europepmc   +1 more source

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide [PDF]

, 2015
Ashley M. Hopkins, Agnès Vitry, Catherine O’Doherty, Susanna Proudman, Michael D. Wiese   +4 more
openalex   +1 more source

Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. [PDF]

Rheumatology (Oxford)
Ahmed S, Pfeiffer RM, Jackson SS, Song M, Mariette X, Seror R, Engels EA.   +6 more
europepmc   +1 more source

Initiation of Disease-Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late-Onset Rheumatoid Arthritis. [PDF]

ACR Open Rheumatol, 2023
Lee J, Martindale J, Makris UE, Singh N, Yung R, Bynum JPW.   +5 more
europepmc   +1 more source

Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis [PDF]

, 2015
Shunsuke Mori
openalex   +1 more source

Correction to "Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry". [PDF]

ACR Open Rheumatol
europepmc   +1 more source

Structural and Functional Outcomes in Rheumatoid Arthritis After 10-Year Therapy with Disease-Modifying Antirheumatic Drugs Under Tight Control: Evidence from Real-World Cohort Data. [PDF]

J Clin Med
Mori S, Okada A, Shimizu T, Takatani A, Koga T.   +4 more
europepmc   +1 more source

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Arthritis care & research, 2012
J. Singh, D. Furst, A. Bharat, J. Curtis, A. Kavanaugh, J. Kremer, L. Moreland, J. O'dell, K. Winthrop, T. Beukelman, S. L. Bridges, W. Chatham, H. Paulus, M. Suarez‐Almazor, C. Bombardier, M. Dougados, D. Khanna, Charles King, Amye Leong, E. Matteson, J. Schousboe, Eileen M. Moynihan, K. Kolba, Archana Jain, E. Volkmann, Harsh Agrawal, S. Bae, A. Mudano, N. Patkar, K. Saag   +29 more
semanticscholar   +1 more source

Serum nitric oxide and peroxynitrite levels in adult sero-positive rheumatoid arthritis treated with disease modifying antirheumatic drugs: a preliminary report

, 2010
Marwan S.M. Al-Nimer, SAMIR ABDUL-HASSAN AL-OBAIDI, KHALID S. AL-DULAIMI   +2 more
openalex   +2 more sources

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns. [PDF]

J Manag Care Spec Pharm
Merola JF, Welby S, Roque H, Song J, Pilipczuk O, Lu C, Walsh JA.   +6 more
europepmc   +1 more source